Denali Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Denali Therapeutics

09/08/2023 01:34

* Denali Therapeutics Inc  DNLI.OQ  reported quarterly
adjusted
earnings of $1.30​​ per share for the quarter ended in June. The
mean expectation of thirteen analysts for the quarter was for a
loss of 68 cents per share.
    * Revenue rose 460.4% to $294.12 million from a year ago;
analysts
expected $13.46 million. 
    * Denali Therapeutics Inc's reported EPS for the quarter was
$1.30​.
    * The mean earnings estimate of analysts had fallen by
about 2.6%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Denali Therapeutics Inc shares had fallen by 11.6% this
quarter and lost 6.2% so far this year.
    * The company reported quarterly net income of $183.38
million.
    * Wall Street's median 12-month price target for Denali
Therapeutics Inc is $54.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 9 at 12:34 a.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.68          1.30           Beat
 Mar. 31 2023      -0.70          -0.80          Missed
 Dec. 31 2022      -0.79          -0.75          Beat
 Sep. 30 2022      -0.81          -0.84          Missed